Literature DB >> 18293412

GlialCAM, an immunoglobulin-like cell adhesion molecule is expressed in glial cells of the central nervous system.

Linda Favre-Kontula1, Alexandre Rolland, Lilia Bernasconi, Maria Karmirantzou, Christine Power, Bruno Antonsson, Ursula Boschert.   

Abstract

Using structure based genome mining targeting vascular endothelial and platelet derived growth factor immunoglobulin (Ig) like folds, we have identified a sequence corresponding to a single transmembrane protein with two Ig domains, which we cloned from a human brain cDNA library. The cDNA is identical to hepatocyte cell adhesion molecule (hepaCAM), which was originally described as a tumor suppressor gene in liver. Here, we show that the protein is predominantly expressed in the mouse and human nervous system. In liver, the expression is very low in humans, and is not detected in mice. To identify the central nervous system (CNS) regions and cell types expressing the protein, we performed a LacZ reporter gene assay on heterozygous mice in which one copy of the gene encoding the novel protein had been replaced with beta-galactosidase. beta-galactosidase expression was prominent in white matter tracts of the CNS. Furthermore, expression was detected in ependymal cells of the brain ventricular zones and the central canal of the spinal cord. Double labeling experiments showed expression mainly in CNPase positive oligodendrocytes (OL). Since the protein is predominantly expressed in the CNS glial cells, we named the molecule glial cell adhesion molecule (GlialCAM). A potential role for GlialCAM in myelination was supported by its up-regulation during postnatal mouse brain development, where it was concomitantly expressed with myelin basic protein (MBP). In addition, in vitro, GlialCAM was observed in various developmental stages of OL and in astrocytes in processes and at cell contact sites. In A2B5 positive OL, GlialCAM colocalizes with GAP43 in OL growth cone like structures. Overall, the data presented here indicate a potential function for GlialCAM in glial cell biology. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18293412     DOI: 10.1002/glia.20640

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  22 in total

Review 1.  Systematic approaches to central nervous system myelin.

Authors:  Patricia de Monasterio-Schrader; Olaf Jahn; Stefan Tenzer; Sven P Wichert; Julia Patzig; Hauke B Werner
Journal:  Cell Mol Life Sci       Date:  2012-03-23       Impact factor: 9.261

2.  Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation and autism.

Authors:  Tania López-Hernández; Margreet C Ridder; Marisol Montolio; Xavier Capdevila-Nortes; Emiel Polder; Sònia Sirisi; Anna Duarri; Uwe Schulte; Bernd Fakler; Virginia Nunes; Gert C Scheper; Albert Martínez; Raúl Estévez; Marjo S van der Knaap
Journal:  Am J Hum Genet       Date:  2011-03-17       Impact factor: 11.025

3.  Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1) due to a homozygous deep intronic splicing mutation (c.895-226T>G) abrogated in vitro using an antisense morpholino oligonucleotide.

Authors:  Cecilia Mancini; Giovanna Vaula; Laura Scalzitti; Simona Cavalieri; Enrico Bertini; Chiara Aiello; Cinzia Lucchini; Richard A Gatti; Alessandro Brussino; Alfredo Brusco
Journal:  Neurogenetics       Date:  2012-05-03       Impact factor: 2.660

4.  Functional significance of the hepaCAM gene in bladder cancer.

Authors:  Yunfeng He; Xiaohou Wu; Chunli Luo; Lie Wang; Jie Lin
Journal:  BMC Cancer       Date:  2010-03-08       Impact factor: 4.430

5.  Structural determinants of interaction, trafficking and function in the ClC-2/MLC1 subunit GlialCAM involved in leukodystrophy.

Authors:  Xavier Capdevila-Nortes; Elena Jeworutzki; Xabier Elorza-Vidal; Alejandro Barrallo-Gimeno; Michael Pusch; Raúl Estévez
Journal:  J Physiol       Date:  2015-06-23       Impact factor: 5.182

6.  Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations.

Authors:  Tanit Arnedo; Chiara Aiello; Elena Jeworutzki; Maria Lisa Dentici; Graziella Uziel; Alessandro Simonati; Michael Pusch; Enrico Bertini; Raúl Estévez
Journal:  Neurogenetics       Date:  2013-11-08       Impact factor: 2.660

7.  GlialCAM, a protein defective in a leukodystrophy, serves as a ClC-2 Cl(-) channel auxiliary subunit.

Authors:  Elena Jeworutzki; Tania López-Hernández; Xavier Capdevila-Nortes; Sònia Sirisi; Luiza Bengtsson; Marisol Montolio; Giovanni Zifarelli; Tanit Arnedo; Catrin S Müller; Uwe Schulte; Virginia Nunes; Albert Martínez; Thomas J Jentsch; Xavier Gasull; Michael Pusch; Raúl Estévez
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 8.  Regulatory-auxiliary subunits of CLC chloride channel-transport proteins.

Authors:  Alejandro Barrallo-Gimeno; Antonella Gradogna; Ilaria Zanardi; Michael Pusch; Raúl Estévez
Journal:  J Physiol       Date:  2015-09-15       Impact factor: 5.182

9.  Autism-epilepsy phenotype with macrocephaly suggests PTEN, but not GLIALCAM, genetic screening.

Authors:  Maria Marchese; Valerio Conti; Giulia Valvo; Francesca Moro; Filippo Muratori; Raffaella Tancredi; Filippo M Santorelli; Renzo Guerrini; Federico Sicca
Journal:  BMC Med Genet       Date:  2014-02-27       Impact factor: 2.103

10.  Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy.

Authors:  Angela Sánchez; Belén García-Lareu; Meritxell Puig; Esther Prat; Jesús Ruberte; Miguel Chillón; Virginia Nunes; Raul Estévez; Assumpció Bosch
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.